​

Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADPT Stock Forecast

Adaptive Bio (ADPT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $12.33, with a high of $18.00 and a low of $5.00. This represents a 59.92% increase from the last price of $7.71.

- $4 $8 $12 $16 $20 High: $18 Avg: $12.33 Low: $5 Last Closed Price: $7.71

ADPT Stock Rating

Adaptive Bio stock's rating consensus is Hold, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (33.33%), 7 Hold (58.33%), 1 Sell (8.33%), and 0 Strong Sell (0.00%).

Hold
Total 12 0 1 7 4 Strong Sell Sell Hold Buy Strong Buy

ADPT Forecast vs Benchmarks

TypeNameUpside
StockAdaptive Bio59.92%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$5.00
Last Closing Price$7.71$7.71$7.71
Upside/Downside---35.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25332--8
Dec, 24332--8
Nov, 24342--9
Oct, 24342--9
Sep, 24342--9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 04, 2024Mark MassaroBTIG$5.00$2.6886.57%-35.15%
Dec 21, 2022David WestenbergPiper Sandler$14.00$7.0997.46%81.58%
Aug 17, 2022David WestenbergPiper Sandler$12.00$11.553.90%55.64%
Jun 13, 2022David WestenbergPiper Sandler$7.50$6.977.60%-2.72%
May 06, 2022Morgan Stanley$18.00$8.15120.86%133.46%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2024BTIGBuyBuyhold
Oct 02, 2024BTIGBuyBuyhold
Apr 04, 2024BTIGBuyBuyhold
Jan 05, 2023ScotiabankSector Outperforminitialise
Dec 21, 2022Piper SandlerNeutralOverweightupgrade
Dec 21, 2022CitigroupNeutralinitialise
Aug 17, 2022Piper SandlerNeutralNeutralhold
Jun 13, 2022Piper SandlerNeutralinitialise
Apr 25, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.06$-1.46$-1.00$-1.56---
Avg Forecast$-1.08$-1.49$-1.47$-1.41$-1.12$-0.94$-0.67
High Forecast$-1.13$-1.56$-1.53$-1.44$-1.12$-1.03$-0.89
Low Forecast$-1.01$-1.40$-1.41$-1.40$-1.11$-0.83$-0.52
Surprise %-1.85%-2.01%-31.97%10.64%---

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$98.38M$154.34M$185.31M$170.28M---
Avg Forecast$95.07M$152.83M$185.10M$172.93M$177.62M$210.66M$264.13M
High Forecast$90.32M$145.20M$179.67M$168.57M$174.90M$204.25M$262.77M
Low Forecast$98.34M$158.09M$190.53M$183.72M$179.32M$216.88M$265.49M
Surprise %3.49%0.99%0.11%-1.54%---

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-139.64M$-205.61M$-142.46M$-225.25M---
Avg Forecast$-135.94M$-232.25M$-258.20M$-225.25M$-160.99M$-141.48M$-100.85M
High Forecast$-163.12M$-278.70M$-309.84M$-270.30M$-162.43M$-148.21M$-128.21M
Low Forecast$-108.75M$-185.80M$-206.56M$-180.20M$-159.55M$-120.32M$-74.91M
Surprise %2.72%-11.47%-44.82%----

ADPT Forecast FAQ

Is Adaptive Bio stock a buy?

Adaptive Bio stock has a consensus rating of Hold, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Adaptive Bio is a neutral investment for most analysts.

What is Adaptive Bio's price target?

Adaptive Bio's price target, set by 12 Wall Street analysts, averages $12.33 over the next 12 months. The price target range spans from $5 at the low end to $18 at the high end, suggesting a potential 59.92% change from the previous close price of $7.71.

How does Adaptive Bio stock forecast compare to the average forecast of its sector, industry, and investment themes?

Adaptive Bio stock forecast shows a 59.92% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Adaptive Bio over the past three months?

  • January 2025: 37.50% Strong Buy, 37.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 37.50% Strong Buy, 37.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 33.33% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Adaptive Bio’s EPS forecast?

Adaptive Bio's average annual EPS forecast for its fiscal year ending in December is -1.12 for 2024, a -28.21% decrease from the reported $-1.56 in 2023. The prediction for 2025 is $-0.94, and $-0.67 for 2026.

What is Adaptive Bio’s revenue forecast?

Adaptive Bio's average annual revenue forecast for its fiscal year ending in December is $177.62M for 2024, a 4.31% increase from the reported $170.28M in 2023. The forecast for 2025 is $210.66M, and $264.13M for 2026.

What is Adaptive Bio’s net income forecast?

For its fiscal year ending in December, Adaptive Bio's average annual net income forecast is $-161M for 2024, reflecting a -28.53% decrease from the reported $-225M in 2023. The projection for 2025 is $-141M, and $-101M for 2026.